Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Assessing the relative efficacy of new drugs: an emerging opportunity


The increasing availability of individual-level data from clinical trials could allow the relative efficacy of new drugs to be assessed in a robust, cost-effective and timely way.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Bombardier, C. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520–1528 (2000).

    Article  CAS  Google Scholar 

  2. EUnetHTA WP5 Joint Action 2 Strand A. Rapid Relative Effectiveness Assessment of pharmaceuticals. Pilot assessment using the HTA Core Model® for rapid relative effectiveness assessment: canagliflozin for the treatment of type 2 diabetes mellitus [online]

  3. Schneeweiss S. et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 5, 480–486 (2012).

    Article  Google Scholar 

  4. Strom, B. et al. Data sharing, year 1 — access to data from industry-sponsored clinical trials. N. Engl. J. Med. 371, 2052–2054 (2014).

    Article  Google Scholar 

  5. Keener, A. B. Group seeks standardisation for what clinical trials must measure. Nature Med. 20, 798–799 (2014).

    Article  CAS  Google Scholar 

Download references


S.S. is partially funded by grants/contracts from the Patient-Centered Outcomes Research Institute, the US Food and Drug Administration and the NIH.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Hans-Georg Eichler.

Ethics declarations

Competing interests

S. S. is a consultant to WHISCON, LLC and to Aetion, Inc., a software manufacturer in which he also owns equity. He is the principal investigator of investigator-initiated grants to the Brigham and Women's Hospital from Novartis, Genentech and Boehringer Ingelheim that are unrelated to the topic of this study.

Supplementary information

Supplementary information S1 (figure)

The trade-off between scientific (internal) validity and feasibility of study designs for Relative Efficacy Assessment (REA). (PDF 111 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Eichler, HG., Thomson, A., Eichler, I. et al. Assessing the relative efficacy of new drugs: an emerging opportunity. Nat Rev Drug Discov 14, 443–444 (2015).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research